Provectus Biopharmaceuticals Announces the Release of Pharmaceutical Grade Rose Bengal … |

KNOXVILLE, TN, Jan. 10, 2022 (GLOBE NEWSWIRE) – Provectus (OTCQB: PVCT) today announced that preclinical research on a pharmaceutical grade formulation of Rose Bengal against Gram-positive (G +) bacteria has been published in Molecules, an open access chemistry journal.

The article, titled “Antibacterial Activity of Pharmaceutical Grade Rose Bengal: An Application of a Synthetic Dye in Antibacterial Therapies”, can be viewed at:

This work, led by Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences, College of Pharmacy, was conducted under a sponsored research agreement between the University of Tennessee Health Sciences Center at Memphis , Tennessee and Provectus.

Dr Kurosu and his colleagues have shown that:

A formulation of the high purity, pharmaceutical grade rose bengal drug substance of Provectus (abbreviated in the article as HP-RBf) killed a battery of G + bacteria, including drug resistant strains, at low concentrations of Within minutes under fluorescent lights, LEDs, and natural light, HP-RBf eradicated G + bacterial biofilms, including drug-resistant strains, The frequency with which G + bacteria spontaneously developed resistance to HP-RBf was extremely low, Based on the toxicity data from their research, HP-RBf may be feasible as an anti-infective drug for the treatment of skin and soft tissue infections (STBBIs) involving multidrug-resistant microbial invasion (MDR) of the skin, and based on whole genome sequencing and analysis of an HP-RBf resistant mutant generated, the antibacterial activity of HP-RBf under low darkness conditions t involve multiple cooperative action mechanisms.

Dominic Rodrigues, Vice Chairman of the Company’s Board of Directors, said: “We are grateful to Dr Kurosu and his team for their scientific research. These activity data and the favorable safety profile of the pharmaceutical grade rose bengal drug substance from Provectus support the advancement of a drug formulation in the clinic as a broad spectrum antibacterial agent. Dr. Kurosu’s work also strongly complements research on antipathogens carried out by other Provectus collaborators.

Mr. Rodrigues added, “Provectus’ pharmaceutical grade rose bengal drug substance is produced through a proprietary 21st century manufacturing process, using quality principles from design under good manufacturing practice. commercial scale, which systematically synthesizes the company’s rose bengal molecule. The Provectus process primarily prevents the formation of substance-bound contaminants and other contaminants found in commercial grade rose bengal, which is made primarily using the 19th century Gnehm process.

About Provectus

Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company that develops immunotherapy drugs for different disease areas based on a class of small molecules called halogenated xanthenes which includes rose bengal sodium. Information on the Company’s clinical trials is available in the National Institutes of Health (NIH) registry, For more information about Provectus, please visit the company’s website at


The information contained in this press release may include “forward-looking statements” within the meaning of United States securities laws relating to the activities of Provectus and its affiliates, which are based on the opinions and estimates of the management of the Company and are subject to various risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “budget”, “plan”, “continue”, “estimate”, “expect”, ” predict, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “could”, “should”, “believe” and similar words suggesting future results or statements regarding a prospect.

The safety and efficacy of the agents and / or uses under study have not been established. There is no guarantee that the agents will receive approval from health authorities or become commercially available in a country for the uses investigated or that these agents as products will achieve particular income levels.

Because of the risks, uncertainties and assumptions inherent in forward-looking statements, readers should not place undue reliance on such forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or the date specifically specified herein, and Provectus assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise, except in accordance with applicable securities laws. Forward-looking statements are expressly qualified by this cautionary statement.

The risks, uncertainties and assumptions include those discussed in documents filed by the Company with the SEC, including those described inand.



Provectus Biopharmaceuticals, Inc. Heather Raines, CPA Chief Financial Officer Phone: (866) 594-5999

Copyright 2022 GlobeNewswire, Inc.

Source link